Last reviewed · How we verify
GW003
At a glance
| Generic name | GW003 |
|---|---|
| Sponsor | Jiangsu T-Mab Biopharma Co.,Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects (PHASE1)
- Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer (PHASE1)
- Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW003 CI brief — competitive landscape report
- GW003 updates RSS · CI watch RSS
- Jiangsu T-Mab Biopharma Co.,Ltd portfolio CI